The Longevity LetterMedications
🚨 NEW GLP-1 Agonist: The Triple Threat That’s Changing Medicine!
Hillary Lin, MD·
🚨 NEW GLP-1 Agonist: The Triple Threat That’s Changing Medicine!Meet Retatrutide—a groundbreaking triple-agonist targeting GIP, GLP-1, and glucagon. 🌟 Early tri…
This issue was originally published in The Longevity Letter.
Subscribe to get the full archive and new issues every Friday.
Subscribe to The Longevity LetterThe Longevity Letter
A weekly read on tests, treatment, and claims.
New issues look at what the evidence supports, what is premature, and what to skip.